<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drugDebug/PMC6901432/results/search/test_trace/results.xml">
  <result pre="combination with acyclovir, in particular for topical preparations for the" exact="treatment" post="of immunocompromised individuals who are more likely to suffer"/>
  <result pre="pump inhibitors are the most frequently prescribed drugs for the" exact="treatment" post="and prophylaxis of gastroesophageal reflux as well as of"/>
  <result pre="analogue acyclovir and its pro-drug valacyclovir are used for the" exact="treatment" post="of disease caused by herpes simplex virus 1 (HSV-1)"/>
  <result pre="Immune staining also indicated reduced numbers of virus-infected cells after" exact="treatment" post="with a combination of omeprazole and acyclovir compared to"/>
  <result pre="a combination of omeprazole and acyclovir compared to either single" exact="treatment" post="(Figure 1B). In agreement, Western blot analysis demonstrated strongly"/>
  <result pre="first line drug for HSV-1, HSV-2, and varicella zoster virus" exact="infection" post="(Piret and Boivin, 2016; Klysik et al., 2018), in"/>
  <result pre="chloroquine and ammonium chloride are known to interfere with the" exact="infection" post="of viruses including HSV. These drugs increase intracellular pH"/>
  <result pre="antiviral activity of acyclovir during the viral replication cycle after" exact="infection" post="and virus internalization. The proton pump inhibitors pantoprazole, rabeprazole,"/>
  <result pre="herpes labialis, which is not commonly associated with severe complications," exact="treatment" post="success is not always satisfactory as highlighted by the"/>
  <result pre="and Boivin, 2016; Karrasch et al., 2018). Moreover, ocular HSV" exact="infection" post="is a major cause of blindness in industrialized countries"/>
  <result pre="in industrialized countries (Klysik et al., 2018). Thus, more effective" exact="treatment" post="options for HSV-1- and HSV-2-caused disease are highly desirable."/>
  <result pre="acidification by chloroquine analogs as a promising strategy for the" exact="treatment" post="of emerging viral diseases.Pharmacol. Res. Perspect.5:e00293. 10.1002/prp2.29328596841 BalzaE.PiccioliP.CartaS.LavieriR.GattornoM.SeminoC.et al."/>
  <result pre="al. (2017). Efficacy and safety of nucleoside antiviral drugs for" exact="treatment" post="of recurrent herpes labialis: a systematic review and meta-analysis.J."/>
  <result pre="Rev. Microbiol.9382–394. 10.1038/nrmicro255921494278 JordanP. C.StevensS. K.DevalJ. (2018). Nucleosides for the" exact="treatment" post="of respiratory RNA virus infections.Antivir. Chem. Chemother.26:2040206618764483. 10.1177/204020661876448329562753 KärberG."/>
  <result pre="zur kollektiven Behandlung pharmakologischer Reihenversuche [A contribution to the collective" exact="treatment" post="of a pharmacological experimental series].Archiv. für Experimentelle Pathologie und"/>
  <result pre="major mouse organs.Antiviral. Res.162130–135. 10.1016/j.antiviral.2018.12.01730605724 KlysikK.PietraszekA.KarewiczA.NowakowskaM. (2018). Acyclovir in the" exact="treatment" post="of Herpes viruses - a review.Curr. Med. Chem.[Epub ahead"/>
  <result pre="Canada: 5% acyclovir and 1% hydrocortisone topical cream in the" exact="treatment" post="of herpes labialis.Skin Therapy Lett.195–8. 25188362 PiretJ.BoivinG. (2016). Antiviral"/>
  <result pre="Antiviral resistance in herpes simplex virus and varicella-zoster virus infections:" exact="diagnosis" post="and management.Curr. Opin. Infect. Dis.29654–662. 10.1097/qco.000000000000028827306564 SalataC.CalistriA.ParolinC.BaritussioA.PalùG. (2017). Antiviral"/>
 </snippets>
</snippetsTree>
